Introduction {#s1}
============

The human CYP3A enzymes are regarded as the most prominent Cytochrome P450 (CYP) subfamily in facilitating the elimination of drugs, other xenobiotic compounds and endogenous molecules from the body (Lamba et al., [@B17]). The pharmacogenetically relevant CYP3A4 is responsible for metabolizing 50--60% of all clinically prescribed drugs (Guengerich, [@B14]) and is listed among The Pharmacogenetics and Pharmacogenomics Knowledge Base\'s (PharmGKB\'s) "very important pharmacogenes" (<http://www.pharmgkb.org/gene/PA130?tabType=tabVip>). CYP3A4 can be inhibited by drugs (e.g., ketoconazole and ritonavir) and is often involved in unfavorable drug-drug interactions, due to its ability to accommodate two or more similar or dissimilar molecules in its active site (Sevrioukova and Poulos, [@B26]). The enzyme is predominantly expressed in the liver and small intestine (Shimada and Guengerich, [@B27]). Expression has as much as 40-fold variation between individual human livers and a 10-fold variation in the metabolism of CYP3A4 substrates *in vivo* (Shimada and Guengerich, [@B27]; Lown et al., [@B19]; Guengerich, [@B14]). While complex regulatory pathways and environmental factors are important, it is suspected that a portion of this inter-individual variation can be attributed to genetic variants located within the coding gene regions as well as its core regulatory regions, which affect either the expression level or the functional protein of the gene (Steimer and Potter, [@B28]; Lamba et al., [@B17]).

Few pharmacogenetically-relevant polymorphisms have been identified in the *CYP3A4* gene; however, some polymorphisms have been associated with, amongst others, immunosuppressant dose requirements (Elens et al., [@B10]), clopidogrel response variability (Angiolillo et al., [@B2]), and withdrawal symptoms and adverse reactions in patients receiving methadone treatment (Chen et al., [@B3]). Furthermore, a rare haplotype, *CYP3A4^\*^20*, results in a complete loss of function (Westlind-Johnsson et al., [@B37]), while *CYP3A4^\*^1B* is suspected to alter the expression levels of CYP3A4 (Westlind et al., [@B36]), although conflicting results have been reported (Wang et al., [@B34]). Although genetic variants in the *CYP3A4* gene have been extensively studied in populations such as Caucasians, Asians, and African-Americans, little research has been conducted in present-day African populations, including those indigenous to South Africa (Warnich et al., [@B35]). Not only are these research disparities observed in candidate gene studies, but they also extend to recent large scale re-sequencing projects such as the 1000 Genomes Project, which although comprehensively examining the genomic variation present in many individuals, provides no information for South African populations (1000 Genomes Consortium, 2010).

We have therefore tried to aid in addressing the disparity of pharmacogenetic data that exists for South African populations by analyzing three of the diverse population groups, which are representative of: (1) the most ancient population group: the Khoisan, (2) the most globally-admixed population group: the South African Mixed Ancestry (MA) population, and (3) the largest language family in South Africa: the Bantu-speaking population group, represented by the Xhosa population. The ancient Khoisan population used in this study consisted of individuals from the !Kung and Khwe linguistic groups (Chen et al., [@B4]). These individuals are descendant from people of the latter Stone Age and are believed to be some of the first lineages of *Homo sapiens* (Kaessmann and Pääbo, [@B16]). The MA population, with Xhosa, Khoisan, European, and Asian ancestral contributions, has been shown to exhibit the highest levels of admixture across the globe (Tishkoff et al., [@B33]) and is therefore of interest for pharmacogenetic applications as genetic variants present in many different populations may affect these individuals as has been reported for other admixed populations such as those from Brazil (Suarez-Kurtz, [@B29], [@B30]; Suarez-Kurtz et al., [@B31]). Lastly, 9 of the 11 official South African languages are classified as Bantu languages (Warnich et al., [@B35]), spoken by \~75% of the total South African population, and therefore it is imperative that representatives of this group are included in pharmacogenetic research. In this study, we utilized the Xhosa population, which are representative of the Nguni-speaking tribes (Warnich et al., [@B35]) and are the biggest Bantu-speaking population in the Western Cape of South Africa, where this research was conducted.

In our experience, it is important that pharmacogenes, such as the *CYP* genes are comprehensively characterized in South African populations, as we have discovered both novel alleles and unique variation profiles for the *CYP2C19* and *CYP2D6* genes (Drögemöller et al., [@B7]; Wright et al., [@B39]). It is hoped that the comprehensive characterization of *CYP3A4* in these populations will aid future *CYP3A4* genotype-phenotype studies in African populations to determine whether functionally relevant *CYP3A4* polymorphisms exist that have an impact on drug metabolism phenotype. We therefore screened the 5′-flanking region and thirteen exonic regions of the *CYP3A4* gene in the three South African populations described above in order to determine which common allelic variants, novel or previously characterized, are present.

Materials and methods {#s2}
=====================

Clinical samples
----------------

Ethical approval was obtained for this study from the Human Research Ethics Committee of Stellenbosch University (S12/07/190) and informed consent was acquired from all participants. Genomic DNA (gDNA) was available for 29 Khoisan, 65 Xhosa, and 65 MA healthy individuals. The Khoisan samples used in this study were collected from !Kung and Khwe speaking individuals from the Schmidtsdrift region of the Kalahari desert in the Northern Cape Province of South Africa (Chen et al., [@B4]), while samples from the Xhosa and MA populations were collected from the Western Cape Province of South Africa.

Polymerase chain reaction (PCR) amplification
---------------------------------------------

Primers were designed to amplify \~600 bp of the 5′-upstream region and all 13 exons with flanking intronic regions of *CYP3A4* (GenBank: AF280107.1; Ensembl ID: ENSG00000160868) (refer to Table [1](#T1){ref-type="table"} for primer sequences). PCR amplifications were carried out in a total reaction volume of 25 μl, with each reaction containing 20--30 ng of gDNA, 10 pmol of each primer, 320 μM dNTPs, 4 mM MgCl~2~, 0.5 U BIOTAQ™ DNA polymerase and 1X Reaction Buffer. All reagents were supplied by Bioline, London, UK. The reaction cycle conditions consisted of an initial denaturation step at 94°C for 3 min, followed by 30 cycles of 15 s denaturation at 94°C, 15 s annealing at varying temperatures (refer to Table [1](#T1){ref-type="table"} for specific annealing temperatures), and 30 s extension at 72°C, with a final extension at 72°C for 5 min.

###### 

**Sequencing Primers and PCR conditions**.

  **Region**    **Primer name**               **Sequence (5′-3′)**            ***T*~*m*~ (°C)**   **Product size (bp)**
  ------------- ----------------------------- ------------------------------- ------------------- -----------------------
  5′-upstream   5′\_F                         CAG AAG GGA TGA CAT GCA GA      60                  767
  5′\_R         GGC TAT GTG CAT GGA GCT TT                                                        
  Exon 1        E1_F                          GAT TCT TTG CCA ACT TCC AAG     60                  363
  E1_R          GAT TAG CAC CCC AAG TCC AA                                                        
  Exon 2        E2_F                          GCA GGA AAG GAC CTG ATG AA      60                  323
  E2_R          AAG CTG CTC TTG GCA ATC AT                                                        
  Exon 3        E3_F                          TGA CGT CTC CAA ATA AGC TTC C   60                  301
  E3_R          AGG TTG ACA AGA GCT TCA TCC                                                       
  Exon 4        E4_F                          AGG ATC AAA GTC TGG CTT CC      60                  305
  E4_R          GGA TGA AGT GGA CGT GGA AC                                                        
  Exon 5        E5_F                          TCT AGC ATA GGG CCC ATC AC      60                  352
  E5_R          CA GTG GAC TAC CCC TTG GAA                                                        
  Exon 6        E6_F                          CCA AGG GGT AGT CCA CTG AA      55                  362
  E6_R          GGA ATA ACC CAA CAG CAG GA                                                        
  Exon 7        E7_F                          TGG AGT GTG ATA GAA GGT GA      55                  516
  E7_R          TTG TGA CAG GGG GCT GAT AG                                                        
  Exon 8        E8_F                          TGC TCC AGG TAA ATT TTG CAC     60                  369
  E8_R          CAA ACC CCA CTT TCT GCA TT                                                        
  Exon 9        E9_F                          CAT CCT GCT TTC CAA GGA         60                  418
  E9_R          CCT GCA TGC CTC TAG AAA GTG                                                       
  Exon 10       E10_F                         TGA TGC CCT ACA TTG ATC TGA     60                  391
  E10_R         CTG CCA GTA GCA ACC ATT TG                                                        
  Exon 11       E11_F                         CCC GAA TGC TTC CCA CCT         60                  506
  E11_R         GGC AGA ATA TGC TTG AAC CAG                                                       
  Exon 12       E12_F                         GAC TGA AAG CTC CTA TAG TGT C   60                  598
  E12_R         CCA TGC TAA TCT ACA TGG GCT                                                       
  Exon 13       E13_F                         GCC ATC ATA CCT AAT AAT CTG G   60 Xhosa            988
  E13_R         AT GTG CAG GAA AGC ATC TGA    55 Others                                           

5′, 5′-upstream; E, exon; F, forward; R, reverse.

DNA sequencing
--------------

To identify common *CYP3A4* genetic variation occurring in each of the three populations, 15 individuals were randomly selected from every population groups for bi-directional sequence analysis, allowing for detection of alleles with a frequency of more than 10%, with 95% confidence. The PCR products from each of the 13 amplicons were purified with SureClean (Bioline) and bi-directionally sequenced using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, CA, USA), after which capillary electrophoresis was performed by the Central Analytical Facility of Stellenbosch University on a 3130*xl* Genetic Analyser (Applied Biosystems). The obtained sequences were subsequently compared to the reference sequence (GenBank: AF280107.1; Ensembl ID: ENSG00000160868) to detect the presence of variants. The generated sequence data also served to ensure that the reaction conditions used did not amplify any of the associated *CYP3A4* isoforms or pseudogenes. The effect of the detected variants was determined using the software programs Sorting Intolerant From Tolerant (SIFT), Polymorphism Phenotyping (PolyPhen) and the Alternative Splice Site Predictor (ASSP) (<http://www.es.embnet.org/~mwang/assp.html>; Ramensky et al., [@B22]; Ng and Henikoff, [@B20]).

Genotyping of the detected variants
-----------------------------------

To determine the frequencies of the genetic variants detected in the 5′-flanking region and the coding regions of the *CYP3A4* gene through sequence analysis, an additional 14 individuals from the Khoisan population and 50 individuals each from the Xhosa and MA populations were genotyped using a combination of restriction fragment length polymorphism (RFLP) analysis and additional sequence analyses. In cases where no restriction sites were created or destroyed by the SNPs of interest, mutagenic primers were designed to introduce artificial restriction enzyme recognition sequences (refer to Table [2](#T2){ref-type="table"} for the primer sequences used for RFLP genotyping). Amplification using the mutagenic primers was performed by means of a nested PCR, using 1 in 200 dilutions of PCR product as template, to avoid co-amplification of isoforms and pseudogenes. The nested PCR conditions were identical to those used during original PCR amplification, except that the cycle number and MgCl~2~ concentration were changed to 25 cycles and 2 mM, respectively (refer to Table [2](#T2){ref-type="table"} for annealing temperatures). To ensure that the RFLP assays were successful, samples with known genotypes were selected as controls for each of the individual restriction enzyme analyses. Due to the large number of variants detected in the exon 7 amplicon, all the individuals from all three of the population groups were sequenced for this region, rather than utilizing individual RFLP genotyping assays. Additionally, due to the fact that the RFLP genotyping assay for rs57409622 in exon 6 would detect both the presence of this SNP and the adjacent rs4986907 (allele defining SNP of *CYP3A4^\*^15*), any individuals testing positive for this assay underwent bi-directional sequencing to determine which one, or both, of the SNPs were in fact present. For genotyping specifications, including a list of the specific restriction enzymes used, refer to Table [2](#T2){ref-type="table"}.

###### 

**PCR_RFLP primers, PCR conditions, and genotyping assays**.

  **Position in gene**   **Allele**                            **rs number**                                     **Genotyping assay**   **Primer name**   **Sequence (5′-3′)**                            ***T*~*m*~ (°C)**   **Product size (bp)**
  ---------------------- ------------------------------------- ------------------------------------------------- ---------------------- ----------------- ----------------------------------------------- ------------------- -----------------------
  −392 A\>G              *CYP3A4*^\*^*1B*                      rs2740574                                         *Mbo*II                5′\_F_m1          GGA CAG CCA TAG AGA CAA GGG **g**A              55                  350
  5′\_R                  GGC TAT GTG CAT GGA GCT TT                                                                                                                                                                           
  −292 T\>G                                                    Novel                                             *Rsa*I                 5′\_F             CAG AAG GGA TGA CAT GCA GA                      55                  575
                         5′\_R_m                               CCT CCT TTG AGT TCA TAT TCT ATG AGG TAT C**g**T                                                                                                                
  −215 T\>A                                                    rs144721069                                       *Hpy188*III            5′\_F_m2          TGT GTG TGT GAT TCT TTG CCA ACT TC**t c**AG G   55                  181
                         5′\_R                                 GGC TAT GTG CAT GGA GCT TT                                                                                                                                     
  3847 A\>G                                                    Novel                                             *Nla*III               E2_F\_m           GCA GGA AAG GAC CTG ATG AAC A**c**A T           55                  323
                         E2_R                                  AAG CTG CTC TTG GCA ATC AT                                                                                                                                     
  5916 T\>C                                                    rs12721625                                        *Bse*NI                E3_F              TGA CGT CTC CAA ATA AGC TTC C                   60                  301
                         E3_R                                  AGG TTG ACA AGA GCT TCA TCC                                                                                                                                    
  13969 G\>A                                                   Novel                                             *Apo*I                 E5_F              TCT AGC ATA GGG CCC ATC AC                      60                  352
                         E5_R                                  CA GTG GAC TAC CCC TTG GAA                                                                                                                                     
  14268 C\>T             *CYP3A4*^\*^*23*                      rs57409622                                        *Aci*I/Sequencing      E6_F\_m/E6_F      GAT GTG TTG GTG AGA AAT CTG AG**a** C           55                  362/154
  E6_R                   GGA ATA ACC CAA CAG CAG GA                                                                                                                                                                           
  14269 G\>A             *CYP3A4*^\*^*15*                      rs4986907                                         *Aci*I/Sequencing      E6_F\_m/E6_F      GAT GTG TTG GTG AGA AAT CTG AG**a** C           55                  362/154
  E6_R                   GGA ATA ACC CAA CAG CAG GA                                                                                                                                                                           
  15619 A\>G                                                   rs111768354                                       Sequencing                                                                                                   
  15628 C\>T                                                   rs4987159                                         Sequencing                                                                                                   
  15649 A\>T             *CYP3A4*^\*^*24*                      rs113667357                                       Sequencing                                                                                                   
  15753 T\>G                                                   rs2687116                                         Sequencing                                                                                                   
  15783 T\>C                                                   rs4987160                                         Sequencing                                                                                                   
  15804 T\>G                                                   rs28988584                                        Sequencing                                                                                                   
  15837 T\>A                                                   rs12721622                                        Sequencing                                                                                                   
  17829 T\>C                                                   Novel                                             *Psi*I                 E9_F              CAT CCT GCT TTC CAA GGA                         60                  418
                         E9_R                                  CCT GCA TGC CTC TAG AAA GTG                                                                                                                                    
  20230 G\>A             *CYP3A4*^\*^*1G*                      rs2242480                                         *Rsa*I                 E10_F             TGA TGC CCT ACA TTG ATC TGA                     60                  391
  E10_R                  CTG CCA GTA GCA ACC ATT TG                                                                                                                                                                           
  20309 G\>C                                                   rs4986911                                         *Hind*III              E10_F             TGA TGC CCT ACA TTG ATC TGA                     55                  327
                         E10_R\_m                              CAG TGA AAG AAT CAG TGA TTA **a**G                                                                                                                             
  20327 T\>C                                                   rs34738177                                        *Mbo*II                E10_F             TGA TGC CCT ACA TTG ATC TGA                     60                  391
                         E10_R                                 CTG CCA GTA GCA ACC ATT TG                                                                                                                                     
  21896 C\>T             *CYP3A4*^\*^*12*                      rs12721629                                        *Pst*I                 E11_F             CCC GAA TGC TTC CCA CCT                         55                  334
  E11_R\_m               CAT CTT TTT TGC AGA CCC TCT **gc**A                                                                                                                                                                  
  23081 C\>T                                                   rs12721620                                        *HpyCH4*IV             E12_F             GAC TGA AAG CTC CTA TAG TGT C                   60                  598
                         E12_R                                 CCA TGC TAA TCT ACA TGG GCT                                                                                                                                    
  25721 A\>G                                                   rs3735451                                         *BsaJ*I                E13_F             GCC ATC ATA CCT AAT AAT CTG G                   60 Xhosa            988
                         E13_R                                 AT GTG CAG GAA AGC ATC TGA                        55 Others                                                                                                    

5′, 5′-upstream; E, exon; F, forward; R, reverse; m, mutagenic primer; lowercase and bold letters, mutagenic bases for the introduction of restriction enzyme recognition sites.

Statistical analysis
--------------------

Allele frequencies of the *CYP3A4* genetic variants detected in the three population groups were compared using MedCalc Version 12.3.0 (<http://www.medcalc.org/calc/odds_ratio.php>). Furthermore, we compared the frequencies of the allele defining SNPs detected in the three South African populations to the frequencies reported by the 1000 Genomes Browser (<http://browser.1000genomes.org/>) and HapMap Phase I + II Project data (<http://hapmap.ncbi.nlm.nih.gov/>). The 1000 Genomes Browser contains allele frequency information for the African (AFR), American Admixed (AMR), East Asian (ASN) and European (EUR) populations; while the HapMap project contains frequency data for European (CEU), Chinese (CHB), Japanese (JPT) and Nigerian (YRI) populations. Deviations from Hardy-Weinberg equilibrium (HWE) were determined using either a Pearson chi-squared analysis or an analogue to Fisher\'s exact test, depending on observed genotype distribution, in Tools for Population Genetic Analysis (TFPGA) Software v1.3 (<http://www.marksgeneticsoftware.net/tfpga.htm>). *P*-values of \<0.05 were considered statistically significant.

Results {#s3}
=======

Variant detection
-----------------

This study detected 24 SNPs in 45 individuals from three South African populations using *CYP3A4* DNA sequencing. Three of the intronic SNPs and one SNP in the 5′-flanking region are novel. Genotyping of rs12721624 in intron 8 and rs147972695 in intron 12 could not be performed in the entire cohort, due to technical difficulties. Genotyping of the remaining 22 SNPs was successful, and all SNPs were in HWE (refer to Table [3](#T3){ref-type="table"} for the positions and frequencies of the detected SNPs). The previously described alleles *CYP3A4^\*^1B* and *^\*^1G* were present in all three populations, while *CYP3A4^\*^12* and *CYP3A4^\*^15* were only present in the Xhosa population. Furthermore, two novel alleles, designated *CYP3A4^\*^23* and *CYP3A4^\*^24*, which are characterized by the two non-synonymous SNPs, resulting in p.R162W and p.Q200H, were detected. *CYP3A4^\*^24* was present in all three population groups, while *CYP3A4^\*^23* was present in the Xhosa and Khoisan populations. Of particular interest, the amino acid change caused by R162W (*CYP3A4^\*^23*) was predicted by both the SIFT and PolyPhen algorithms to affect the function of the protein product. None of the variants were predicted to alter any splice-sites.

###### 

***CYP3A4* variants detected in the three South African populations**.

  **Position in gene**                          **Allele**                                      **rs number**   **Region**    **Amino acid substitution**   **Allele frequencies (%)**           
  --------------------------------------------- ----------------------------------------------- --------------- ------------- ----------------------------- ---------------------------- ------- -------
  −392 A\>GG\>A                                 *CYP3A4*[^\*^](#TN1){ref-type="table-fn"}*1B*   rs2740574       5′-flanking                                 76.79                        73.02   45.90
  −292 T\>G                                                                                     Novel           5′-flanking                                 7.14                         0.00    0.81
  −215 T\>A                                                                                     rs144721069     5′-flanking                                 0.00                         0.81    0.85
  3847 A\>G                                                                                     Novel           Intron 1                                    0.00                         8.59    0.00
  5916 T\>C                                                                                     rs12721625      Intron 2                                    0.00                         1.56    1.56
  13969 G\>A                                                                                    Novel           Intron 5                                    0.00                         0.00    2.31
  14268 C\>T                                    *CYP3A4*[^\*^](#TN1){ref-type="table-fn"}*23*   rs57409622      Exon 6        R162W                         3.57                         0.77    0.00
  14269 G\>A                                    *CYP3A4*[^\*^](#TN1){ref-type="table-fn"}*15*   rs4986907       Exon 6        R162Q                         0.00                         2.38    0.00
  15619 A\>G                                                                                    rs111768354     Exon 7        G190G                         1.72                         3.85    3.17
  15628 C\>T                                                                                    rs4987159       Exon 7        I193I                         0.00                         4.62    3.17
  15649 A\>T                                    *CYP3A4*[^\*^](#TN1){ref-type="table-fn"}*24*   rs113667357     Exon 7        Q200H                         10.34                        3.08    3.17
  15753 T\>G                                                                                    rs2687116       Intron 7                                    75.86                        77.69   45.38
  15783 T\>C                                                                                    rs4987160       Intron 7                                    10.34                        3.85    3.85
  15804 T\>G                                                                                    rs28988584      Intron 7                                    0.00                         3.85    2.38
  15837 T\>A                                                                                    rs12721622      Intron 7                                    10.34                        10.00   3.85
  17024 C\>T[^\*^](#TN1){ref-type="table-fn"}                                                   rs12721624      Intron 8                                    0.00                         0.00    3.33
  17829 T\>C                                                                                    Novel           Intron 9                                    8.62                         0.78    0.78
  20230 G\>A                                    *CYP3A4*[^\*^](#TN1){ref-type="table-fn"}*1G*   rs2242480       Intron 10                                   91.38                        93.85   60.00
  20309 G\>C                                                                                    rs4986911       Intron 10                                   15.52                        9.68    6.35
  20327 T\>C                                                                                    rs34738177      Intron 10                                   0.00                         1.61    0.78
  21896 C\>T                                    *CYP3A4*[^\*^](#TN1){ref-type="table-fn"}*12*   rs12721629      Exon 11       L373F                         0.00                         2.34    0.00
  23081 C\>T                                                                                    rs12721620      Intron 11                                   1.92                         20.31   10.83
  25721 A\>G                                                                                    rs3735451       Intron 12                                   76.92                        87.70   50.00
  25739 C\>T[^\*^](#TN1){ref-type="table-fn"}                                                   rs147972695     Intron 12                                   0.00                         3.33    0.00

Allele frequencies are given for the variant allele.

Due to RFLP genotyping failure, these SNPs were only genotyped in the 45 sequenced individuals.

Population variant frequency comparisons
----------------------------------------

When examining the successfully genotyped variants in the three South African populations, we noticed that the allele frequencies for several SNPs differed significantly between the population groups (*P* \< 0.05) (refer to Table [4](#T4){ref-type="table"}). The smallest difference was seen when the allele frequencies of the Khoisan and Xhosa populations were compared, with the allele frequencies of three SNPs differing significantly between these two population groups. With regards to the comparisons of (1) the Khoisan and MA populations, and (2) the Xhosa and MA populations, five and six SNPs showed significant allele frequency differences, respectively.

###### 

**All allele defining variants and SNPs displaying significant differences in allele frequencies between the Khoisan (*n* = 29), Mixed Ancestry (*n* = 65), and Xhosa (*n* = 65)**.

  **Position in gene**   **Allele**         **rs number**   **Khoisan-mixed ancestry**   **Khoisan-xhosa**         **Mixed ancestry-xhosa**                                     
  ---------------------- ------------------ --------------- ---------------------------- ------------------------- -------------------------- ------------------------- ------- -------------------------
  −392 A\>GG\>A          *CYP3A4*^\*^*1B*   rs2740574       0.000                        0.257 (0.125--0.525)      0.592                      0.818 (0.392--1.705)      0.000   3.189 (1.876--5.421)
  −292 T\>G                                 Novel           0.619                        1.769 (0.187--16.713)     0.041                      21.343 (1.129--403.534)   0.093   15.894 (0.628--402.140)
  3847 A\>G                                 Novel           0.713                        2.094 (0.041--106.852)    0.094                      0.087 (0.005--1.508)      0.029   0.042 (0.002--0.716)
  14268 C\>T             *CYP3A4*^\*^*23*   rs57409622      0.137                        10.138 (0.478--214.853)   0.206                      4.778 (0.424--53.807)     0.566   0.391 (0.016--9.687)
  14269 G\>A             *CYP3A4*^\*^*15*   rs4986907       0.713                        2.094 (0.041--106.852)    0.430                      0.302 (0.015--5.935)      0.202   0.144 (0.007--2.818)
  15649 A\>T             *CYP3A4*^\*^*24*   rs113667357     0.059                        3.519 (0.953--12.993)     0.053                      3.635 (0.985--13.414)     0.964   1.033 (0.253--4.2220)
  15753 T\>G                                rs2687116       0.000                        0.264 (0.132--0.529)      0.783                      1.108 (0.534--2.298)      0.000   4.191 (2.447--7.180)
  17829 T\>C                                Novel           0.025                        11.981 (1.367--105.025)   0.025                      11.981 (1.367--105.025)   1.000   1.000 (0.062--16.163)
  20230 G\>A             *CYP3A4*^\*^*1G*   rs2242480       0.000                        0.142 (0.053--0.378)      0.540                      1.439 (0.450--4.603)      0.000   10.167 (4.583--22.553)
  21896 C\>T             *CYP3A4*^\*^*12*   rs12721629      0.707                        2.128 (0.042--108.589)    0.437                      0.307 (0.016--6.030)      0.202   0.144 (0.008--2.817)
  23081 C\>T                                rs12721620      0.083                        0.161 (0.021--1.268)      0.013                      0.077 (0.010--0.583)      0.043   0.477 (0.232--0.978)
  25721 A\>G                                rs3735451       0.001                        0.300 (0.143--0.629)      0.076                      2.140 (0.922--4.965)      0.000   7.133 (3.718--13.685)

Variants showing significant differences between the South African populations are indicated in shaded areas (P \< 0.05).

The novel *CYP3A4* alleles, although detected in the South African populations (refer to Table [3](#T3){ref-type="table"}), were present at frequencies of less than 1% in the populations recorded on the 1000 Genomes Browser. When examining the previously described *CYP3A4* alleles, in the case of *CYP3A4^\*^12* and *CYP3A4^\*^15*, the data from the 1000 Genomes Browser was not available for all populations, therefore we utilized frequency data from the HapMap Project. Both of these variants were not detected in any of the HapMap populations, however, it should be noted that frequency data for the *CYP3A4^\*^15* SNP was not available for the YRI population. These SNPs were also absent in the MA and Khoisan populations, but were present in the Xhosa population at a frequency of at 2.3% and 2.4%, respectively. With regards to the remaining potentially functional *CYP3A4* allele, namely *CYP3A4^\*^1B*, the frequencies of this variant in the three South African populations as well as those reported by the 1000 Genomes Browser differed substantially, as demonstrated by Figure [1](#F1){ref-type="fig"}.

![**Distribution of the *CYP3A4^\*^1B* allele frequencies in all three South African populations and the four populations present in the 1000 Genomes Browser.** (AFR, African; AMR, American Admixed; ASN, East Asian; EUR, European).](fgene-04-00017-g0001){#F1}

Discussion {#s4}
==========

*CYP3A4* genetic variation in the three South African populations
-----------------------------------------------------------------

To our knowledge, this was the first study in which the entire coding region of the *CYP3A4* gene was screened for common genetic variation in any Southern African population. This study identified a total of 24 variants in the three South African population groups, which included the discovery of four novel SNPs (i.e., \~17% of the total genetic variation). Overall this study revealed the presence of the previously described *CYP3A4^\*^1B*, *CYP3A4^\*^1G*, *CYP3A4^\*^12*, and *CYP3A4^\*^15* alleles, in addition to two novel alleles, *CYP3A4^\*^23* and *CYP3A4^\*^24*. The number of novel alleles reported here is in accordance with the number of novel alleles that we have detected previously through the re-sequencing of other *CYP* genes in South African populations (Drögemöller et al., [@B7]; Wright et al., [@B39]). Prior to this study, these novel *CYP3A4* alleles had not been recorded on the *CYP* allele database and were present at very low frequencies in the populations described on the 1000 Genomes Browser. Both were present in the Xhosa and Khoisan populations examined in this study and *CYP3A4^\*^24* was additionally detected in the MA population. The p.R162W amino acid change in exon 6, characterizing *CYP3A4^\*^23*, may have functional consequences for the CYP3A4 protein, as arginine is a positively charged and hydrophilic amino acid; while tryptophan is a polar, aromatic and hydrophobic amino acid. The likely functional consequences of this variant are in agreement with the predictions made by both the SIFT and PolyPhen algorithms. Although the p.Q200H variant, characterizing *CYP3A4^\*^24*, was not predicted to change the function of the protein product, the presence of this variant has also been reported in the genome of another Khoisan individual sequenced by Schuster et al. ([@B25]), which correlates to the fact that the frequencies of both novel alleles were highest in the Khoisan population (Drögemöller et al., [@B6]). Additionally, the low frequency of these variants in the 1000 Genomes populations in comparison to the presence of these alleles at varying frequencies in the South African population groups, highlights the unique genomic composition of South African populations. Thus, results obtained from other population groups cannot be directly inferred onto the South African populations and comprehensive re-sequencing studies such as this one are required to characterize South African genomes.

The recent discovery of the *CYP3A4^\*^22* allele confirmed that novel alleles may have functional relevance to the field of pharmacogenetics (Wang et al., [@B34]). This allele was initially found to influence RNA expression and statin dose requirement (Wang et al., [@B34]). These findings have subsequently been replicated with regards to statin therapy and the allele has additionally been shown to influence the dose requirements of the immunosuppressants, tacrolimus, and cyclosporine (Elens et al., [@B10], [@B9]). *CYP3A4^\*^22* is characterized by the intron 6 SNP rs35599367, which, however, was not genotyped in the current study as the aim of the study was to examine only coding regions, including the exon-intron boundaries, and the core promoter region of the gene. Furthermore, this variant does not occur in the 1000 genomes AFR or ASN populations and occurs at very low frequencies (2--5%) in the EUR and AMR populations and is thus unlikely to occur at pharmacogenetically relevant frequencies in the South African populations (<http://browser.1000genomes.org/Homo_sapiens/Variation/Population?r=7:9936581699366816;source=dbSNP;v=rs35599367;vdb=variation;vf=11936818>). The reported functional significance of this intronic *CYP3A4^\*^22* variant does, however, highlight the importance of non-coding regions. The significance of these areas, including regions that are not in close proximity to the gene has been further emphasized by the recent release of the ENCODE data (ENCODE Project Consortium et al., [@B11]). These data suggest that in the future additional analyses to examine the variation present in such areas, including the functional significance of the four novel non-coding SNPs identified by this study, are warranted.

The detection of novel variants in this study highlights the fact that although large re-sequencing studies such as the 1000 Genomes Project have played an integral role in characterizing the human variome (1000 Genomes Consortium, 2010), novel variation still exists, underlining the importance of re-sequencing studies such as this one. These re-sequencing studies are specifically required in African populations, as these populations have been under-represented in genomic studies to date (Rosenberg et al., [@B23]; Drögemöller et al., [@B6]). Furthermore, it may be important to compare results obtained by next generation sequencing studies to those obtained through the use of Sanger sequencing. Although the throughput of next generation sequencing studies is beyond comparison, it may be beneficial to evaluate the accuracy of next generation sequencing for the complex and polymorphic *CYP* genes, whose sequences show high similarity to one another and to their corresponding pseudogenes (Drögemöller et al., [@B6]). This may be particularly important with regards to the genotyping of *CYP3A4*, which shows between 76 and 88% sequence similarity to the *CYP3A43*, *CYP3A5*, and *CYP3A7* genes (<http://www.ensembl.org/Homo_sapiens/Gene/Compara_Paralog?g=ENSG00000160868;r=7:99354604-99381888>) and is thus likely to be affected by the consequences of misalignment or co-amplification of other genes during the use of high-throughput technologies.

Of the previously identified alleles that were detected in this study, both *CYP3A4^\*^1B* and *CYP3A4^\*^12* have been reported to have functional relevance for pharmacogenetic applications. The high frequency *CYP3A4^\*^1B* is characterized by a 5′-upstream c.−392A\>G point mutation in a regulatory element, namely the putative nifedipine-specific element, which has been linked to altered gene expression *in vitro* (Amirimani et al., [@B1]; Georgitsi et al., [@B13]). Furthermore, this allele has been associated with various disease states such as prostate cancer and secondary leukemias (Lamba et al., [@B17]). Of relevance to pharmacogenetic applications, PharmGKB lists this SNP as affecting the metabolism of a number of therapeutic drugs, although the level of evidence for variant-drug associations is still low currently (<http://www.pharmgkb.org/rsid/rs2740574>; Whirl-Carrillo et al., [@B38]). The lack of pharmacogenetic evidence for this allele is further questioned by the results obtained by Wang et al. ([@B34]) and the functional significance of this variant may require further examination. On the other hand, while *CYP3A4^\*^1B* appears to affect the expression of *CYP3A4*, *CYP3A4^\*^12* (p.L373F) affects the protein product. p.L373 has been identified as one of the key residues affecting substrate binding, cooperativity and regioselection of metabolism (Sevrioukova and Poulos, [@B26]) and therefore the amino acid change has been shown to result in a protein that amongst others, displays an altered testosterone metabolite profile and a four-fold increase in the *Km* value for 1′-OH midazolam formation (Eiselt et al., [@B8]). While *CYP3A4^\*^1B* occurs at a relatively high frequency, both *CYP3A4^\*^12* and *CYP3A4^\*^15* occur at low frequencies, possibly limiting the relevance that these two variants may have for pharmacogenetic applications, especially when considering their absence from the HapMap populations. Similarly, the lack of applicability of the SNPs defining *CYP3A4^\*^3, CYP3A4^\*^13, CYP3A4^\*^17*, and *CYP3A4^\*^18* to pharmacogenetics in the South African setting is also likely as they were not detected in this study or a previous study (Ikediobi et al., [@B15]). These conclusions should however, be made with caution, as the relatively frequent occurrence of rare variants in African populations (Tishkoff et al., [@B33]) cannot be ignored and the effect of such variants should possibly also be taken into account when considering the implementation of pharmacogenetics in the African context.

Variant frequency differences between the three South African populations
-------------------------------------------------------------------------

When comparing the significant differences in allele frequencies between the three population groups, it was observed that the three groups differed significantly from one another for eight SNPs (refer to Table [4](#T4){ref-type="table"}). These results reflect the unique genomic compositions of South African populations (Warnich et al., [@B35]) and indicate that the results of one South African population are not always representative of another South African population. When looking at the three populations independently, the Khoisan and Xhosa were shown to be the most similar to one another, while the differences observed between the Khoisan and MA and the Xhosa and MA were comparable. The fact that the MA population showed the greatest number of genetic differences may be explained by the large number of ancestry contributions, other than the Xhosa and Khoisan, that have been made to this population (Schlebusch et al., [@B24]; De Wit et al., [@B5]; Quintana-Murci et al., [@B21]; Warnich et al., [@B35]). The large degree of similarity observed between the Xhosa and Khoisan is to be expected and can be explained by the large ancestry contribution that the Khoisan have made to the Xhosa population (De Wit et al., [@B5]; Warnich et al., [@B35]).

The differences in allele frequencies observed for the *CYP3A4^\*^1* sub-allele, *CYP3A4^\*^1B*, between the different population groups (refer to Figure [1](#F1){ref-type="fig"}), serves as an excellent illustration of how pharmacogenetic applications may differ between population groups. It is important to remember that drugs designed to optimally treat one population group based on the presence of a certain allele, may be harmful to another population group for which the opposite allele is dominant. Figure [1](#F1){ref-type="fig"} shows how the *CYP3A4^\*^1B* allele is more frequent in the African populations (Khoisan, Xhosa and AFR), while in the ASN and EUR population groups the opposite allele occurs more often. Interestingly, both the MA and AMR admixed populations show allele frequencies that are intermediate between the African and EUR/ASN populations. Furthermore, the MA is more similar to the African populations, while the AMR is more similar to the non-African populations. These results are in accordance with the ancestral history of these population groups. The MA have ancestry contributions from the Xhosa, Khoisan, European, and Asian populations (Schlebusch et al., [@B24]; Tishkoff et al., [@B33]; De Wit et al., [@B5]; Quintana-Murci et al., [@B21]), which explains why although the frequencies of the variants in this population are between the African and EUR/ASN populations, they are more similar to the African populations. On the other hand, the AMR population, which consists of the Mexicans, Puerto Ricans, Columbians, and Peruvians (<http://www.1000genomes.org/faq/which-populations-are-part-your-study>), is more similar to the EUR/ASN population groups due to the larger ancestry contribution that these populations have made to the AMR, when compared to the ancestry contribution of Africans (Galanter et al., [@B12]).

The allele frequency differences observed in admixed populations, as previously reported in admixed Brazilian populations (Suarez-Kurtz, [@B29], [@B30]; Suarez-Kurtz et al., [@B31]), bring to light an important consideration for the implementation of pharmacogenetics. Individuals within admixed populations are likely to exhibit different levels of ancestry contributions, as has been shown with the use of STRUCTURE analyses for both the MA (Tishkoff et al., [@B33]) and Brazilian populations (Suarez-Kurtz, [@B30]). Population based pharmacogenetic testing is thus unlikely to detect all pharmacogenetically relevant variants and it may be necessary to implement pharmacogenetics on an individualized level. In the context of South Africa with its diverse population groups, which exhibit both rare variants and variants from several different population sources (Warnich et al., [@B35]), this may be especially important. However, before this goal can be realized it will be necessary to consider whether individualized treatment will be feasible in the resource limited settings of the country.

Conclusions {#s5}
===========

Although this study identified both novel and known SNPs of functional significance in all three population groups, due to the current lack of validated evidence regarding the pharmacogenetic application of *CYP3A4*, the relevance of these SNPs in the clinical setting remains unknown. The SNP markers detected in the current study should therefore be included in genotyping panels in future pharmacogenetic association studies involving CYP3A4 substrate medications. Nonetheless, this study provides an excellent example of how re-sequencing studies are required in African populations in order to identify variation that remains novel. These differences in allele frequencies were not only seen when comparing the South African populations to other populations, but also when comparing them to each other. These results demonstrate that a one-size-fits-all approach is not ideal when implementing therapeutic treatment regimes, also within the South African context.
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